Healius (ASX:HLS) reported Thursday that its underlying loss per diluted share in the fiscal first half narrowed to AU$0.0279, from a loss of AU$0.031 per diluted share a year earlier.
Analysts polled by FactSet were expecting a loss of AU$0.01 per share.
Revenue for the six months ended Dec. 31, 2024, was AU$662.3 million, up from AU$620.8 million in the same period a year earlier. Analysts surveyed by FactSet expected sales of AU$913 million.
The healthcare company expects fiscal 2025 earnings before interest and taxes from Agilex Biolabs to be similar to last year's AU$5.1 million.
The company's shares were down past 4% in recent Thursday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。